SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB


               QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


          For the Quarterly Period Ended     Commission File Number

                    OCTOBER 31, 1999                  0-9922
                    ----------------                  ------


                          AMERICAN ELECTROMEDICS CORP.
                          ----------------------------
        (Exact Name of Small Business Issuer as Specified in its Charter)



                      DELAWARE                       04-2608713
                      --------                       ----------
         (State or Other Jurisdiction           (IRS Employer ID No.)
          of Incorporation or Organization)


            13 COLUMBIA DRIVE, SUITE 5, AMHERST, NEW HAMPSHIRE 03031
            --------------------------------------------------------
              (Address and Zip Code of Principal Executive Offices)

          Issuer's telephone number, including area code: 603-880-6300
                                                          ------------

    Securities registered pursuant to Section 12(b) of the Exchange Act: NONE
                                                                         ----

      Securities registered pursuant to Section 12(g) of the Exchange Act:


                     COMMON STOCK, PAR VALUE $.10 PER SHARE
                     --------------------------------------
                                (Title of Class)


Indicate by check mark whether the Issuer (1) has filed all reports  required to
be filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months,
and (2) has been subject to such filing requirements for the past 90 days. YES X
NO __


As of  December  13,  1999,  there  were  outstanding  14,761,600  shares of the
Issuer's Common Stock, $.10 par value.




<PAGE>

                          AMERICAN ELECTROMEDICS CORP.


                                      Index
                                      -----

                                                                            Page
                                                                            ----
PART I - FINANCIAL INFORMATION

Item 1.  Consolidated Financial Statements

     Consolidated Balance Sheets, October 31, 1999 and
      July 31, 1999...........................................................3

     Consolidated Statements of Operations for the Three
      Months Ended October 31, 1999 and October 31, 1998......................4

     Consolidated Statements of Cash Flows for the Three
      Months Ended October 31, 1999 and October 31,1998.......................5

     Notes to Consolidated Financial Statements...............................6

Item 2.  Management's Discussion and Analysis or Plan of Operation............9

PART II - OTHER INFORMATION

Item 2. Changes in Securities................................................10

Item 6. Exhibits and Reports on Form 8-K.....................................10

SIGNATURES...................................................................11











                                      -2-
<PAGE>

PART I  -  FINANCIAL INFORMATION

Item 1.  CONSOLIDATED FINANCIAL STATEMENTS

                  AMERICAN ELECTROMEDICS CORP. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS

                                                  October 31,        July 31,
                                                     1999              1999
                                                ---------------- --------------
                                                  (Unaudited)
Assets                                                     (Thousands)
Current Assets:
Cash and cash equivalents....................              $1,071        $  210
Accounts receivable..........................                 777           897
Inventories..................................               1,552         1,480
Prepaid and other current assets.............                 219           196
                                                 ---------------- --------------
        Total current assets.................               3,619         2,783

Property and Equipment.......................                 754           745
Accumulated depreciation.....................                (152)         (115)
                                                 ---------------- --------------
                                                              602           630
Goodwill.....................................                 708           715
Patents......................................               2,807         2,897
Other........................................                 632           216
                                                 ---------------- --------------
                                                           $8,368        $7,241
                                                 ================ ==============
Liabilities & Stockholders' Equity
Current Liabilities:
Bank debt....................................              $  509        $1,073
Accounts payable.............................               1,244         1,784
Accrued liabilities..........................                 648           815
Dividends payable............................                 514           373
                                                 ---------------- --------------
   Total current liabilities.................               2,915         4,045

Minority interest in consolidated subsidiary.               1,507           440

Stockholders' Equity:
Preferred stock, $.01 par value;
 Authorized-1,000,000 shares:
  Series A Convertible; Outstanding- 2,400 shares           1,909         1,909
  Series B Convertible; Outstanding- 1,170 shares             982           982
Common stock, $.10 par value;
 Authorized - 20,000,000 shares;
  Outstanding - 9,830,955 and 9,637,621 shares at
  October 31, 1999 and July 31, 1999, respectively            983           963
Additional paid-in capital.................                16,080        14,837
Retained deficit...........................               (15,661)      (15,541)
Accumulated other comprehensive loss.......                  (240)         (200)
                                                 ---------------- --------------
                                                            4,053         2,950
Deferred compensation......................                  (107)         (194)
                                                 ---------------- --------------
         Total stockholder's equity........                 3,946         2,756
                                                ----------------- --------------
                                                           $8,368        $7,241
                                                 ================ ==============

                             See accompanying notes.





                                      -3-
<PAGE>



                  AMERICAN ELECTROMEDICS CORP. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
                                                  Three Months Ended October 31,
                                                  ------------------------------
                                                         1999           1998
                                                   --------------- -------------
                                           (Thousands, except per share amounts)


Net sales.....................................              $   802    $  2,150
Cost of goods sold............................                  502       1,263
                                                    --------------- ------------
   Gross profit...............................                  300         887

Selling, general and administrative expenses..                1,253       1,922
Research and development......................                  136         128
                                                    --------------- ------------

   Total operating expenses...................                1,389       2,050
                                                    --------------- ------------
Operating loss................................               (1,089)     (1,163)

Other income (expenses):

   Gain on sale of subsidiary capital stock...                  862            -
   Interest, net..............................                  (12)        (17)
   Minority interest in affiliate.............                  113            -
   Other......................................                    6        (106)
                                                    --------------- ------------
                                                                969        (123)
                                                    --------------- ------------

Net loss......................................              $  (120)   $ (1,286)
                                                    =============== ============
Net loss attributable
 to common stockholders*......................              $  (261)   $ (1,403)
                                                    =============== ============
Weighted average number of common and common
equivalent shares outstanding.................            9,798,732   7,064,636
                                                    =============== ============

Net loss per share, basic and diluted.........              $  (.03)   $   (.20)
                                                    =============== ============

                             See accompanying notes.

*    The  quarters  ended  October 31, 1999 and 1998  include the impact of
     $141,000 and $117,000,  respectively, of dividends on Preferred Stock.



                                      -4-
<PAGE>



                  AMERICAN ELECTROMEDICS CORP. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)

                                                   Three Months Ended October 31
                                                   -----------------------------
                                                        1999           1998
                                                   ---------------- ------------
Operating activities:                                         (Thousands)
Net loss.......................................            $  (120)     $(1,286)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization..................                 185         132
Deferred compensation amortization.............                  87         432
Gain on sale of subsidiary capital stock.......                (862)          -
Minority interest .............................                (113)          -
Changes in operating assets and liabilities:
  Accounts receivable..........................                 108        (206)
  Inventories, prepaid and other current assets                (120)       (402)
  Accounts payable and accrued liabilities.....                (622)        532
                                                   ---------------- ------------
Net cash used in operating activities..........              (1,457)       (798)

Investing activities:
Proceeds from sale of subsidiary capital stock.               1,638           -
Purchase of property and equipment, net........                (494)        (36)
                                                   ---------------- ------------
Net cash provided by (used in)
 investing activities..........................               1,144         (36)

Financing activities:
Net proceeds (payments) on debt and bank
 lines-of-credit...............................                (549)        682
Issuance of common stock, net..................                 100         (79)
Issuance of capital stock by consolidated
 subsidiary....................................               1,635           -
Proceeds from exercise of common stock options.                   -          15
                                                   ---------------- ------------
Net cash provided by financing activities......               1,186         618
                                                   ---------------- ------------
Effect of exchange rate on cash................                 (12)          1
                                                   ---------------- ------------
Increase (decrease) in cash and cash equivalents                861        (215)
Cash and cash equivalents, beginning of period                  210         396
                                                   ---------------- ------------
Cash and cash equivalents, end of period.......              $1,071        $181
                                                   ================ ============

Noncash transaction:
Common stock issued for services...............              $   75           -

                             See accompanying notes.



                                      -5-
<PAGE>


                  AMERICAN ELECTROMEDICS CORP. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                OCTOBER 31, 1999
                                   (Unaudited)


1. BASIS OF PRESENTATION
   ---------------------

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information.  Accordingly,  they do not include all of the information
and footnotes required by generally accepted accounting  principles for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been  included.  Operating  results for the three month period ended October 31,
1999 are not necessarily  indicative of the results that may be expected for the
year  ending July 31,  2000.  For further  information,  refer to the  financial
statements and footnotes thereto included in the Company's annual report on Form
10-KSB for the year ended July 31, 1999.

Foreign Currency Translation

     The  financial  statements of the Company's  foreign  subsidiary  have been
translated into U.S. dollars in accordance with Statement of Financial Standards
No. 52,  Foreign  Currency  Translation.  All balance  sheet  amounts  have been
translated  using  the  exchange  rates in  effect at the  balance  sheet  date.
Statement of Operations  amounts have been  translated  using  average  exchange
rates.  The gains and losses  resulting  from the changes in exchange rates from
the date of  acquisition  of Rosch GmbH to October 31,  1999 have been  reported
separately as a component of  stockholders  equity.  The  aggregate  transaction
gains and losses are insignificant.

Comprehensive Income (Loss)

     Effective  August 1, 1998,  the  Company  adopted  Statement  of  Financial
Accounting Standard No. 130, Reporting Comprehensive Income (SFAS 130). SFAS 130
establishes new rules for the reporting and display of  comprehensive  income or
loss and its components,  however,  the adoption of this statement had no impact
on the Company's net income or shareholders'  equity. For the three months ended
October 31, 1999, the Company's only item of other comprehensive  income was the
foreign  currency  translation  adjustment  recognized in  consolidation  of its
partially-owned   German   subsidiary,   Rosch  GmbH.  SFAS  130  requires  such
adjustments,  which prior to adoption were reported  separately in shareholders'
equity,  to be  included in other  comprehensive  income.  Prior year  financial
statements have been reclassified to conform to the requirements of SFAS 130.

     The foreign currency translation  adjustment and comprehensive loss for the
three months ended October 31, 1999 was $(40,000) and ($160,000),  respectively.
As of October 31, 1999, the cumulative  translation  adjustment and  accumulated
other comprehensive loss was ($240,000).
Going Concern

     The accompanying financial statements have been prepared on a going concern
basis,  which  contemplates  the  realization of assets and the  satisfaction of
liabilities  in the  normal  course  of  business.  As  shown  in the  financial
statements,  the Company has incurred a net loss of $120,000 for the three month
period ended October 31, 1999. In addition,  the Company  incurred a net loss of
$9,861,000  for the year ended July 31, 1999.  This and other  factors  indicate
that the Company may be unable to continue as a going  concern for a  reasonable
period of time.

     The  financial  statements do not include any  adjustments  relating to the
recoverability  of  assets  and  classification  of  liabilities  that  might be
necessary  should the  Company be unable to  continue  as a going  concern.  The
Company's  continuation  as a going  concern is  dependent  upon its  ability to
generate  sufficient  cash flow to meet its  obligations  on a timely basis,  to
obtain additional financing and ultimately to attain profitability.  The Company
continues  to pursue  strategies  to improve  the  profitability  of its current
product lines, and is actively pursuing additional debt and equity financing.


2. DEBT
   ----

     The  Company's  50.01% owned German  subsidiary,  Rosch GmbH  Medizitechnik
("Rosch  GmbH")  has two term  loans  and two  revolving  lines of  credit  with
German-based  banks.  During the three month period ended October 31, 1999,  the
total outstanding balance under these loans decreased by approximately  $564,000
based upon  scheduled  payments  under the term loans and  principal  repayments
under the lines of credit made based upon the Company's cash position.

                                      -6-
<PAGE>



3. INVESTMENT IN AFFILIATE
   -----------------------

     In  September  1999,  a  minority  shareholder  of Rosch GmbH  acquired  an
additional  24.99% of Rosch GmbH through two  transactions  consisting  of (1) a
capital  contribution into Rosch GmbH of approximately  $1.6 million,  and (2) a
direct purchase of a portion of the Company's  ownership  interest in Rosch GmbH
for approximately $1.6 million.  These transactions  resulted in the recognition
of a gain on the sale of Rosch GmbH capital stock of approximately $862,000, and
a reduction  in the  Company's  ownership  percentage  of Rosch GmbH from 75% to
50.01%.  As the Company  continues to maintain a  controlling  interest in Rosch
GmbH,  it  continues  to  consolidate  the  operations  of  Rosch  GmbH.   These
transactions resulted the recognition of an increase in the minority interest in
the consolidated subsidiary in the amount necessary to bring that interest up to
the current minority  ownership  percentage of 49.99% of Rosch GmbH's net assets
as of October 31,  1999,  or  $1,067,000.  This  amount  includes  the  minority
stockholders'  share of Rosch GmbH's net losses for the three month period ended
October 31, 1999, which was approximately $113,000.


4. EQUITY
   ------

     During the three month period ended October 31, 1999, the Company closed on
a private  placement for 133,334  shares of its Common Stock for  $100,000,  and
issued 60,000  shares of its Common Stock,  plus a five-year warrant to purchase
up to 20,000 shares of the Company's  Common Stock at an exercise price of $1.25
per share, as consideration  for $75,000 of prior services.  These  transactions
were with "accredited investors",  as such term is defined in Regulation D under
the Securities Act.


5. YEAR 2000
   ---------

     The Year 2000 Issue is the result of computer  programs being written using
two digits rather than four to define the applicable  year. Any of the Company's
computer programs or hardware that have  date-sensitive  software embedded chips
may recognize a date using "00" as the year 1900 rather than the year 2000. This
could  result in a system  failure or  miscalculations  causing  disruptions  of
operations,  including,  among other  things,  a temporary  inability to process
transactions, send invoices, or engage in similar normal business activities.

     The  Company  has  completed  its plan to resolve the Year 2000 Issue which
involved  the  following  four  phases:  assessment,  remediation,  testing  and
implementation.  The assessment indicated that most of the Company's significant
information  technology  systems  would be  affected,  including  its  financial
information system which includes its general ledger, accounts payable,  billing
and  inventory  systems.  The  assessment  was also  undertaken on the Company's
products,  however, following the sale of the audiometrics assets in April 1999,
the  Company no longer  sells  products  which  utilize  software  and  hardware
(embedded  chips) which could  require  remediation  to be Year 2000  compliant.
Accordingly, the Company does not believe that the Year 2000 presents a material
exposure as it relates to the Company's  products.  The Company's  manufacturing
processes consist principally of unautomated assembly of components manufactured
by outside third-parties.  The Company has begun to gather information about the
Year  2000  compliance  status  of its  significant  suppliers,  and  will  take
appropriate steps to monitor their compliance on an ongoing basis.

     Regarding its information  technology  exposures,  the Company  utilizes an
unmodified  off-the-shelf  software  package.  The  Company  has  purchased  and
installed a year  2000-compliant  upgrade,  and is now fully year 2000 compliant
with respect to its financial  information  systems,  and as the new software is
also an unmodified off-the-shelf package, testing to ensure Year 2000 compliance
is not necessary.

     The  Company  does  not  presently  maintain  direct  interfaces  with  any
third-party  vendors.  The Company has made various  queries of its  significant
suppliers  that do not share  information  systems  with the  Company  (external
agents).  To date,  the Company is not aware of any  external  agent with a Year
2000 issue that would  materially  impact the Company's  results of  operations,
liquidity,  or capital resources.  However, the Company has no means of assuring
that external  agents will be Year 2000 ready.  The inability of external agents
to  complete  their  Year 2000  resolution  process  in a timely  fashion  could
materially  impact the Company.  The effect of non-compliance by external agents
is not determinable.


                                      -7-
<PAGE>



     The total cost of the Company's Year 2000 project was approximately $5,000.
The project costs consisted  principally of the cost of new software,  which has
been capitalized.

     Management  of the Company  believes it has  effectively  resolved the Year
2000 Issue.  However,  exposure  continues  to exist  relative to the  Company's
outside  suppliers,  which  could  have  a  materially  adverse  effect  on  its
manufacturing and shipping operations.  In addition,  disruptions in the economy
generally resulting from Year 2000 issues could also materially adversely affect
the Company.  The Company  currently  has no  contingency  plans in place in the
event of an  unforeseen  Year 2000  problem.  The  Company  plans to continue to
monitor its suppliers, and will develop such a plan if necessary.


6. SUBSEQUENT EVENTS
   -----------------

     Effective   November  15,  1999,  the  Company  closed  an  agreement  (the
"Fukushima  Agreement") with Jim Fukushima,  a director and Vice Chairman of the
Company,  whereby Mr. Fukushima purchased 800,000 shares of the Company's Common
Stock,  a  three-year  warrant to  purchase up to 300,000  additional  shares of
Common Stock at an exercise price of $2.00 per share and a 5% ownership interest
in Rosch GmbH, through a sub-participation contract with Andy Rosch, the general
manager of Rosch GmbH,  in exchange  for a payment of $2 million.  The  proceeds
were used principally for the cash payments  described below. This sale resulted
in the reduction of the Company's ownership percentage in Rosch GmbH to 45.01%.

     Effective  November 16, 1999,  pursuant to an agreement with the holders of
the Company's  outstanding 1,170 shares of Series B Preferred Stock, the Company
redeemed  all such  outstanding  shares,  together  with all  accrued and unpaid
dividends,  penalties  and  redemption  premiums,  in exchange  for a payment of
$1,170,000 in cash and the issuance of 369,000  shares of the  Company's  Common
Stock.

     Effective  November 17, 1999,  pursuant to a Securities  Exchange Agreement
with the holder of the  Company's  outstanding  Series A  Preferred  Stock,  the
Company made a cash payment of $840,000,  issued  2,228,312 shares of its Common
Stock and issued a Promissory  Note and Security  Agreement (the "Secured Note")
in the principal  amount of $1,050,000 in exchange for (i) the conversion  1,350
shares of Series A Preferred Stock and the accrued  dividends on all outstanding
Series A  Preferred  Stock,  (ii)  the  redemption  of 700  shares  of  Series A
Preferred Stock and (iii) the exchange of 350 shares of Series A Preferred Stock
for the Secured Note. The Secured Note is non-interest  bearing,  due in full on
the  earlier  to occur  of (i) five  business  days of the  closing  date of the
initial public offering in Germany of Rosch GmbH or (ii) April 30, 2000, secured
by certain intellectual property rights of the Company, and the principal amount
may be reduced to  $700,000 if the  average  closing bid price of the  Company's
Common  Stock for the five  trading  days prior to  maturity  exceeds  $3.00 per
share.

     Effective  November 18, 1999, the Company sold  1,333,333  shares of Common
Stock to  Concord  Effekten  AG, a minority  stockholder  of Rosch  GmbH,  for a
purchase price of $1 million.





                                      -8-
<PAGE>



Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION


RESULTS OF OPERATIONS
---------------------

     Net sales for the three month period ended October 31, 1999 were  $802,000,
compared to $2,150,000  for the three month period ended  October 31, 1998.  The
Company's sale of its  audiometrics  business assets in April 1999 resulted in a
decrease  in sales of  approximately  $357,000 as compared to the same period in
the prior fiscal year. The remainder of the decrease in sales is attributable to
the Company's shift in focus towards its INJEX(TM) needle-free injection system,
and away from the intraoral dental camera equipment market.

     Cost of sales  for the three  month  periods  ended  October  31,  1999 and
October 31, 1998 were 62.6% and 58.7% of net sales,  respectively.  The decrease
is attributable to the continual decline in gross profit margins  experienced in
the intraoral dental camera equipment market, resulting primarily from increased
competition in that marketplace.

     Selling,  general and  administrative  expenses  for the three month period
ended  October  31,  1999  were  $1,253,000,  compared  to  $1,922,000  for  the
comparable prior year period.  The decrease reflects the impact of the Company's
sale of its  audiometrics  business  assets in April  1999,  and cost  reduction
measures  implemented within DDS in anticipation of the sale of that subsidiary.
Also contributing to the net decrease was a reduction of approximately  $345,000
of  amortization  expense due primarily to deferred  compensation  recognized in
connection with the acquisitions of DDS and ESI. This deferred  compensation was
fully amortized  during the fiscal year ended July 31, 1999.  These decreases in
expense were partially  offset by increased  costs  incurred in connection  with
ESI, and its  preparation  for full-scale  market  introduction of the INJEX(TM)
System.

     Net loss for the three month  period ended  October 31, 1999 was  $120,000,
compared to a net loss of  $1,286,000,  for the same period in the prior  fiscal
year.  The  decrease in net loss is primarily  the result of the  $862,000  gain
recognized on the partial sale of the Company's ownership in Rosch GmbH. The net
loss for the three month period ended October 31, 1999 was also decreased by the
sale of the  audiometrics  business  assets  in  April  1999  and the  decreased
business activity within the intraoral dental equipment business,  both of which
resulted in  significant  losses during the three months ended October 31, 1998.
These decreases in the Company's net loss were partially offset by the increased
costs incurred in connection with ESI and its preparation for full-scale  market
introduction of the INJEX(TM) System.



LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

     Working  capital of the Company at October 31, 1999 was $704,000,  compared
to $(1,262,000) at July 31, 1999. The increase of $1,966,000  resulted primarily
from the proceeds from the sale of a portion of the Company's ownership in Rosch
GmbH of  approximately  $1.6 million and the proceeds from the capital  infusion
into Rosch GmbH by a minority  stockholder of  approximately  $1.6 million.  The
increases  were  partially  offset by the net effect of the Company's  operating
losses.

     During November 1999, the Company completed certain  transactions which had
significant  impact on its  capital  structure.  All  outstanding  shares of the
Company's Series A and Series B Convertible Preferred Stock were eliminated, via
the issuance of a total of 2,597,312  shares of its Common Stock,  issuance of a
Promissory  Note and Security  Agreement in the principal  amount of $1,050,000,
and a cash payment of $2,010,000.  The  Promissory  Note is due in full no later
than April 30,  2000.  In  addition,  the  Company  sold,  through  two  private
placements,  an  aggregate  of 2,133,333  shares of its Common  Stock,  issued a
three-year  warrant to purchase up to 300,000  shares of its Common  Stock at an
exercise  price of $2.00 per share,  and sold a 5%  ownership  interest in Rosch
GmbH, for gross  proceeds of $3 million.  These  transactions  had a minimal net
impact on working capital,  however,  by eliminating the Preferred Stock, future
working capital requirements for the dividends associated with those shares were
eliminated.


                                      -9-
<PAGE>

     Though the Company has significantly improved its working capital position,
it does not currently  have  sufficient  working  capital to sustain the Company
through  the  expected  time  necessary  to  achieve  positive  cash  flows from
operations.  Additional  working  capital  will be needed,  and  therefore,  the
Company  continues  to  seek  additional  capital  through  equity  and/or  debt
placements or secured  financing;  however,  no assurance can be given that such
financing  arrangements would be successfully  completed immediately and, if so,
on terms not dilutive to existing stockholders.


     The Company's working capital requirements,  along with net losses incurred
of $9,861,000  for the year ended July 31, 1999 and $120,000 for the three month
period ended October 31, 1999, as well as other factors, raise substantial doubt
about  the  ability  of  the  Company  to  continue  as  a  going  concern.  The
accompanying financial statements do not include any adjustments relating to the
recoverability  and  classification  of asset carrying amounts or the amount and
classification  of liabilities that might result should the Company be unable to
continue as a going concern.



PART II. - OTHER INFORMATION

Item 2.  CHANGES IN SECURITIES

     During the three month period ended October 31, 1999, the Company closed on
a private  placement for 133,334  shares of its Common Stock for  $100,000,  and
issued 60,000  shares of its Common Stock,  plus a five-year warrant to purchase
up to 20,000 shares of the Company's  Common Stock at an exercise price of $1.25
per share, as consideration  for $75,000 of prior services.  These  transactions
were with "accredited investors",  as such term is defined in Regulation D under
the Securities Act.

     During November 1999, the Company completed the following transactions:

     |X|  An  agreement  (the  "Fukushima  Agreement")  with  Jim  Fukushima,  a
          director  and Vice  Chairman of the  Company,  whereby  Mr.  Fukushima
          purchased  800,000 shares of the Company's  Common Stock, a three-year
          warrant to purchase up to 300,000 additional shares of Common Stock at
          an exercise  price of $2.00 per share and a 5%  ownership  interest in
          Rosch GmbH, through a sub-participation  contract with Andy Rosch, the
          general  manager  of Rosch  GmbH,  in  exchange  for a  payment  of $2
          million.

     |X|  The  Company  redeemed  all  1,170  outstanding  shares  of  Series  B
          Preferred  Stock,  together  with all  accrued  and unpaid  dividends,
          penalties and redemption  premiums,  in exchange for a cash payment of
          $1,170,000 and the issuance of 369,000 shares of the Company's  Common
          Stock.

     |X|  Pursuant to a  Securities  Exchange  Agreement  with the holder of the
          Company's  outstanding  Series A Preferred  Stock,  the Company made a
          cash payment of $840,000,  issued 2,228,312 shares of its Common Stock
          and issued a Promissory  Note and  Security  Agreement  (the  "Secured
          Note") in the  principal  amount of $1,050,000 in exchange for (i) the
          conversion  1,350  shares of Series A Preferred  Stock and the accrued
          dividends  on all  outstanding  Series  A  Preferred  Stock,  (ii) the
          redemption  of 700  shares of Series A  Preferred  Stock and (iii) the
          exchange  of 350 shares of Series A  Preferred  Stock for the  Secured
          Note.  The Secured Note is  non-interest  bearing,  due in full on the
          earlier to occur of (i) five  business days of the closing date of the
          initial  public  offering  in  Germany of Rosch GmbH or (ii) April 30,
          2000, secured by certain intellectual  property rights of the Company,
          and the  principal  amount may be reduced to  $700,000  if the average
          closing bid price of the  Company's  Common Stock for the five trading
          days prior to maturity exceeds $3.00 per share.

     |X|  Effective  November 18, 1999,  the Company  sold  1,333,333  shares of
          Common Stock to Concord  Effekten AG, a minority  stockholder of Rosch
          GmbH, for a purchase price of $1 million.

     All  shares  issued  under the  above  transactions  were with  "accredited
investors",  as such term is defined in Regulation D under the  Securities  Act.
See Form 8-K filed for events as of November 15, 1999 for further information.

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

None.

Exhibits -

27.      Financial Data Schedule
                                      -10-
<PAGE>



                                   SIGNATURES
                                   ----------

     In accordance  with the  requirements  of the Exchange Act, the  registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                          AMERICAN ELECTROMEDICS CORP.
                          ----------------------------


  /s/Thomas A. Slamecka              Dated:   October 15, 1999
--------------------------
Thomas A. Slamecka
Chairman
(Principal Executive Officer)


 /s/Michael T. Pieniazek             Dated:   October 15, 1999
--------------------------
Michael T. Pieniazek
President and
Chief Financial Officer
(Principal Financial Officer)


                                      -11-
<PAGE>


EXHIBIT INDEX

Exhibit                       Description
-------                       -----------
27                            Financial Data Schedule